INTRODUCTION {#S1}
============

Hepatitis B virus (HBV) infection is a main public health problem with 2 billion people infected throughout the world and 350 million suffering from chronic HBV infection and 75% of them are Asians ([@R1]). Iran is located in the low endemic area for HBV infection ([@R2]). The hepatitis B surface antigen (HBsAg) prevalence in Iran varied from 0 to 3.9% in different provinces ([@R3]).

The main strategy for effective control of the HBV infection is administration of three intramuscular doses of HBV vaccine. It has been reported that HBV vaccination elicits excellent immunogenicity and protective efficacy in more than 90% of healthy adults and more than 95% of infants, children and adolescents ([@R4]-[@R6]). However, approximately 5-10% of immunized individuals fail to develop detectable specific antibodies and remain at risk for hepatitis B infection ([@R7]). HBV vaccination has been implemented for newborns since 1992 in Iran ([@R8]). After 13 years of HBV vaccine administration, the vaccine coverage raised from 62% in 1993 to 94% in 2005 ([@R2]).

Although the overall rates of HBV vaccines efficacy are high, some factors have been associated with low responsiveness to HBV vaccine such as increasing age, male gender, obesity, tobacco consumption, administration of vaccine in the buttock instead of deltoid muscle and genetic factors such as certain HLA groups ([@R9], [@R10]). Moreover, an investigation showed that hepatitis B core antibody (anti-HBc) positivity is also associated with lack of hepatitis B surface antibody (anti-HBs) development after HBV vaccination and most of these cases assumed to have occult HBV infection ([@R11]).

Occult HBV infection is considered as the detection of HBV-DNA in the liver or serum with undetectable HBsAg with or without HBV antibodies ([@R12]). Occult HBV infection is a worldwide entity and its distribution is affected by the general prevalence of the HBV in various populations and geographical areas ([@R13]).

Occult HBV was well described in some high risk groups such as hemodialysis patients, HIV infected cases and injection drug users ([@R14]-[@R16]). Some studies have demonstrated that failure of HBV vaccine is associated with presence of HBV-DNA in sera ([@R17], [@R18]). Additionally, the emergence of HBV variants with mutations in the S gene, mostly developing in the "a" determinant region might be contributed in failure of HBV vaccine which had been reported in several regions of the world ([@R19], [@R20]).

Despite identification of risk factors for poor response to HBV vaccine in some population; the presence of occult HBV infection in adult subjects with HBV vaccine failure is not studied well. So we conducted this survey to assess the presence of occult HBV infection in adult populations who failed to respond to two full HBV vaccine series.

PATIENTS AND METHODS {#S2}
====================

In this cross-sectional study, 52 healthy employees who were non-responder to HBV vaccine (two full HBV vaccine series) were recruited in Tehran, Iran. Ethical clearance was taken from ethical committee of the Iranian Society for Support of Patients with Infectious Diseases and informed consent was obtained from all patients before enrollment.

A vaccine non-responder is a person who does not develop protective surface antibodies (anti-HBs titer \< 10 IU/L) after completing two full HBV vaccine series \[20 μg of the recombinant HBV vaccine (Pasteur Institute of Iran, Tehran, Iran) at 0, 1 and 6 months\].

Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc) were tested with commercial electrochemiluminescence immunoassay kits (Roche Cobas e 411 analyzer; Roche Diagnostics, Indianapolis, IN, USA).

Subjects with isolated anti-HBc (HBsAg negative, anti-HBs negative and anti-HBc positive) were retested for reactivity to anti-HBc and HBsAg.

HBV-DNA was extracted using High Pure Viral Nucleic Acid kit (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer's instructions. HBV-DNA was determined by real-time PCR using Geno Sen's HBV Real time PCR (Genome Diagnostics, New Delhi, India) on the Rotor-Gene 6000 real-time thermal cycler (Corbett Research, Sydney, Australia). The detection limit of the kit was 100 IU/ml according to the user manual.

Statistical Analysis {#S3}
--------------------

The Chi-square was used with the SPSS 16 Package program for statistical analysis (Chicago, IL, USA). Data are presented as median or, when indicated, as an absolute number and percentage.

RESULTS {#S4}
=======

A total of 52 HBV vaccine non-responders with median age 34 years were enrolled in the study. 63.5% of patients were male and 36.5% were female. Isolated anti-HBc was detected in two (3.8%) subjects. HBV-DNA was detected in none of our cases.

DISCUSSION {#S5}
==========

Presence of HBV-DNA with undetectable HBsAg, regardless of detection of other HBV serological markers, is defined as occult HBV infection ([@R21], [@R22]). The HBV-DNA could be detected with higher frequency in individuals with positive anti-HBc and negative anti-HBs ([@R23]). Description of occult HBV infection has been limited to blood or organ donors ([@R21], [@R24], [@R25]), hemodialysis patients and HIV infected cases ([@R14], [@R15]) and there is few published reports focusing on occult HBV infection in HBV vaccine non-responders.

The World Health Organization has recommended HBV vaccination to all nations since 1992 for eliminating HBV infection. The coverage rate of HBV vaccine was estimated approximately 70% globally in 2009 ([@R26]). However breakthrough infections has been reported infrequently in vaccines and emergence of escape mutants, and low response to vaccine could be the causative factors ([@R27]-[@R29]). Most of the breakthrough infections are relevant to wild type strain of HBV, but "a" determinant mutants of virus frequently reported in HBV vaccinated subjects from different regions of the world ([@R19], [@R20], [@R30]). Hsu study demonstrated a raising prevalence of S mutants 15 years after universal HBV vaccine implementation in infants in Taiwan ([@R30]). Therefore, vaccination can increase the possibility of selection pressure on the emergence of S mutants ([@R31]).

Limited studies are carried out on the presence of occult HBV infection in HBV vaccine non-responders. Yen *et al.* ([@R11]) evaluated the etiology of non-responsiveness to HBV vaccine in adults and showed that the lower response rate to HBV vaccine in isolated anti-HBc positive subjects may be due to occult HBV infection. Occult HBV infection was noted in 78.6% of non-responder subjects with isolated anti-HBc in this study. Although Yen *et al.* ([@R11]) could not find HBV-DNA in their cases and they assumed anti-HBe positive subjects as occult HBV infection.

In a study conducted by Su *et al.* ([@R32]), young adults with isolated anti-HBc who had been fully vaccinated with HBV vaccine at infancy were evaluated for response to HBV booster vaccine. No evidence of occult HBV infection was observed in participants. However we have to consider that isolated anti-HBc may be attributed to resolved HBV infection with loss of anti-HBs or false positive anti-HBc or presence of occult HBV infection.

The results of an investigation by Pande *et al.* ([@R33]) showed that 42% of infants born from HBsAg positive mothers develop occult HBV infection, which is not prevented by HBV vaccine administration to the newborn. HBIG administration at birth could not prevent occult HBV infection, although it prevented the overt HBV infection.

In another investigation by Mu *et al.* ([@R34]) occult HBV infection was documented in 10.9% of HBV vaccinated children. Our study is the first survey on occult HBV infection in HBV vaccine non-responders and showed that its frequency is negligible in non-responders to HBV vaccine even in subjects with isolated anti-HBc. There are some explanations for this situation. Firstly, occult HBV infection does not have a role in HBV vaccine non-responsiveness. Secondly, lack of occult HBV infection was expected in our cases because we also did not find occult HBV infection in our other recent studies in different groups such as blood donors ([@R25]), injection drug users ([@R16]) and dialysis patients (unpublished data). It may be due to the fact that our country is in the low endemic area for HBV infection and also improvement of people's knowledge about the risk factors of HBV transmission. Besides national vaccination program has decreased the HBV incidence in general population and other groups ([@R2]). Finally, isolated anti-HBc is an important marker for occult HBV infection so another cause for lower rate of occult HBV infection in this study can be attributed to low number of isolated anti-HBc in our cases ([@R35]). The national HBV vaccination program may be related to the low prevalence of isolated anti-HBc in Iran.

In conclusion, our investigation showed that occult HBV infection was not a risk factor for poor response to HBV vaccine in our population. This finding should be repeated in future studies with larger cohorts.
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